Dual targeting of the GIST lineage-specific master regulators, ETV1 and KIT, by MEK and KIT inhibitors, respectively, may enhance clinical efficacy of these agents, and more studies should be conducted to explore this combination. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.